It is always a pleasure for the #Dipharma group to be invited to the annual National Congress of the Italian Chemical Society (Società Chimica Italiana – SCI) to contribute scientifically. This year, the XXVIII edition is taking place in Milan, Italy, from August 26th to 30th. On August 29th our colleagues Michela Zuffo, PhD and Roberto Rossi, R&D Researchers, will be presenting as speakers on the following topics: - Michela Zuffo, PhD will present the following oral contribution: “AZIDES MANIPULATION: DANGER IS NOT OUR MIDDLE NAME”. This will focus on our company’s #expertise in safe handling dangerous chemicals and in particular #azides, exploiting it to provide high-quality products and services to our customers. - Roberto Rossi will deliver his lecture on “PURGE RATIO VS SPIKE & PURGE, WHO WINS? A REAL CASE DURING AN API PRODUCTION”. In the quest to meet #Regulatory Agencies’ standards for the production and release of Active Pharmaceutical Ingredients (#APIs), many factors must be considered. Ensuring that the specifications for starting materials and intermediates are stringent enough to produce an API that complies with ICH regulations often requires substantial time and financial investments. But can a theoretical approach, which aims to minimize costs and timelines, truly replace experimental studies while providing the same level of assurance? Roberto Rossi will present a compelling case involving a critical impurity detected in the early stages of synthesizing Sodium Phenylbutyrate. In the work carried out, the theoretical “Purge Ratio” approach of determining the fate of each impurity was compared with the experimental approach of “Spike & Purge” of the impurity previously identified and synthesized. To know more how #Dipharma can accelerate your journey from early-stage development to full-scale manufacturing, please contact us: https://lnkd.in/ermD5P2 To read the abstracts of the two lectures, please refer to https://lnkd.in/dX9FUYJr. Dipharma Francis S.r.l; Dipharma Inc. #SCI, #CDMO, #generics; #API, #activepharmaceuticalingredient, #pharma; #cgmp;
Dipharma Francis S.r.l
Fabbricazione di prodotti farmaceutici
Baranzate, Milano 16.938 follower
Experience you can trust
Chi siamo
The Dipharma Group is a global CDMO and one of the leading family-owned manufacturers of Active Pharmaceutical Ingredients and Intermediates, having a portfolio of more than 40 products, with Drug Master Files lodged worldwide. Dipharma serves top ranking pharmaceutical companies in Europe, U.S.A. and Japan. Supported by a fully equipped R&D Centers, its core technologies are Nitration, Nitroesterification, Azide Chemistry, High Pressure Hydrogenation, Chiral Synthesis, Organometallic Chemistry and Enzymatic Processes.
- Sito Web
-
http://www.dipharma.com/
Link esterno per Dipharma Francis S.r.l
- Settore
- Fabbricazione di prodotti farmaceutici
- Dimensioni dell’azienda
- 501 - 1000 dipendenti
- Sede principale
- Baranzate, Milano
- Tipo
- Società privata non quotata
- Data di fondazione
- 1949
Località
-
Principale
Via Bissone, 5
Baranzate, Milano 20021, IT
-
Via Origgio 23
Caronno Pertusella, Varese 21042, IT
-
Via XXIV Maggio, 40
Mereto di Tomba, Udine 33036, IT
Dipendenti presso Dipharma Francis S.r.l
Aggiornamenti
-
Seeking a reliable and skilled #CDMO partner? #Dipharma has everything you need! Join us at ChemOutsourcing, booth 69, on September 3-6, 2024, in Parsippany, New Jersey. Our #CDMO experts will be delighted to meet you and discuss your #DrugSubstance development and manufacturing requirements. The #DipharmaGroup, a global CDMO and leading producer of Active Pharmaceutical Ingredients and Intermediates, operates as a global leader, managing processes efficiently while maintaining the flexibility and agility to address any challenge, including high-energy chemistry. We employ about 600 dedicated and highly committed employees in Italy and the U.S. Our state-of-the-art R&D centers support the development of robust chemical synthesis, ensuring seamless manufacturing of your Drug Substance across our four #CGMP plants. With a wide range of scale-up capabilities, we have the flexibility, capacity, and experience to expedite your molecule's path to market. Arrange a meeting with us at [email protected] to discover how we can tailor a solution for you! www.dipharma.com. Dipharma Francis S.r.l, Dipharma Inc., #custommanufacturing; #contractmanufacturing ; #customsynthesis; #APIs
-
-
It is always a pleasure to receive recognition that testifies to our commitment to delivering the best solutions to our customers. At #Dipharma, we have just received the Bausch #Award Crystal Vase, in acknowledgment of Bausch Health Companies Inc. recognizing Dipharma as an outstanding supplier. We sincerely thank our esteemed customer, Bausch Health, for awarding Dipharma with the Demonstrates Continuous Improvement #Award 2023. We would like to dedicate this gift to all our employees, whose dedication to continuous improvement has been instrumental in our #success. Your hard work ensures we consistently meet and exceed our customers' expectations. Thank you again, Bausch Health, for this honour and for celebrating our collective accomplishment. Together, let's continue to aim for excellence and reach new achievements. www.dipharma.com Dipharma Francis S.r.l; Dipharma Inc.; #generics; #API, #activepharmaceuticalingredient #pharma; #cgmp;
-
-
Less than three months until CPHI Milan begins! If you are seeking a trusted, experienced, and flexible Active Pharmaceutical Ingredient (API) partner to entrust your projects, look no further. #Dipharma is the right choice, with 75 years of #expertise and a spotless track record of over 50 years of positive inspections by major regulatory agencies like the #FDA, #PMDA, and #AIFA. Join us at CPHI Milan 2024 from October 8-10 at booth 3A41. To schedule a meeting, please contact us: https://lnkd.in/ermD5P2 Discover our comprehensive #CDMO services and explore our portfolio of new #generic #APIs and advanced #intermediates. Our experts are eager to understand your needs and collaborate with you to find the best solutions, accelerating your journey from early-stage development to full-scale manufacturing. For more information, visit our website: www.dipharma.com Dipharma Francis S.r.l ; Dipharma Inc.; #CPHI; #CPHIMilan2024; #CphiMilan, #CDMO; #customsynthesis; #contractmanufacturing, #generics; #ActivePharmaceuticalIngredients; #cgmp, #gmp
-
-
Seeking a reliable and skilled #CDMO partner? #Dipharma has everything you need. Join us at ChemOutsourcing, booth 69, on September 3-6, 2024, in Parsippany, New Jersey. Our #CDMO experts will be delighted to meet you and discuss your #DrugSubstance development and manufacturing requirements. The #DipharmaGroup, a global CDMO and leading producer of Active Pharmaceutical Ingredients and Intermediates, operates as a global leader, managing processes efficiently while maintaining the flexibility and agility to address any challenge, including high-energy chemistry. We employ about 600 dedicated and highly committed employees in Italy and the U.S. Our state-of-the-art R&D centers support the development of robust chemical synthesis, ensuring seamless manufacturing of your Drug Substance across our four #CGMP plants. With a wide range of scale-up capabilities, we have the flexibility, capacity, and experience to expedite your molecule's path to market. Arrange a meeting with us at [email protected] to discover how we can tailor a solution for you! www.dipharma.com. Dipharma Francis S.r.l, Dipharma Inc., #custommanufacturing; #contractmanufacturing ; #customsynthesis; #APIs
-
-
CPHI China 2024 has concluded! At #Dipharma, we extend our gratitude to everyone who participated in fruitful meetings and discussions with us and expressed interest in our solutions. It was a pleasure to connect with you all! For any further details or enquiries, please don't hesitate to contact us at https://lnkd.in/ermD5P2 Dipharma Francis S.r.l, Dipharma Inc., #APIs, #CDMO; #customsynthesis; #contractmanufacturing, #generics, #cphichina #cphichina2024
-
-
The lesson by Alessio Bove, our Pilot Plant Manager at the Italian Dipharma Francis site in Mereto di Tomba (UD), has become a fixed appointment in the University of Pavia’s Master in Drug Design and Development. For several years now, our colleague Alessio Bove has been invited annually to share his expertise. Last week, at the 2024 edition of the Master, Alessio presented “API Production: #technologytransfer and #troubleshooting management”. How does #Dipharma ensure its processes are robust and reproducible? How does the company assess the safety of new processes? Can #Dipharma consistently meet customer deadlines? Alessio addressed these questions in his presentation and detailed how technology transfer is a pivotal phase in #drugdevelopment, greatly influencing the success of both product development and subsequent commercial manufacturing. He explained Dipharma's approach to mastering this complex step by: 1. Gaining comprehensive insights into potentially critical process parameters during the familiarization and optimization stages of process development. 2. Conducting systematic HazOp studies with multidisciplinary teams of experts to identify and mitigate hazards, ensuring the best solutions for process safety management. 3. Implementing a thorough risk management strategy during the preliminary stages of industrial scale-up planning. Alessio Bove also highlighted #Dipharma’s commitment to meeting deadlines through a transparent and realistic timeline estimation process. This is grounded in our extensive #experience and aligned with customer expectations. Our approach involves keeping clients thoroughly informed throughout the process, ensuring clear and consistent communication about project progress. This transparency builds trust and assures clients of our dedication to delivering on time. Our unwavering commitment to robust and reproducible processes, comprehensive safety evaluations, and adherence to production timelines reinforces our pledge to provide the highest #quality products and services to our clients. To know more how we can support you, taking care of your needs: https://lnkd.in/ermD5P2 Dipharma Francis S.r.l; Dipharma Inc.; Università di Pavia; #research; #master; #apis; #CDMO; #cuttingedgetechnology #management #development #safety
-
-
Another appointment related to #Dipharma’s collaboration with the academic world has been scheduled: “The University, National Research Council (CNR) and Industry Meeting” is the title of the conference, which will be held on June 28, in Milan, via Golgi 19. The event has been promoted by the Chemistry department of Università degli Studi di Milano, the Consiglio Nazionale delle Ricerche, and the CNR SCITEC 'Giulio Natta'. It will host various Italian entities committed to promoting #science and #chemistry, discussing some of the most current and relevant issues in scientific and technological #research. The aim of this meeting is to create points of contact between different entities and stimulate fruitful scientific interactions among the key players from the #academicworld, #CNR, and #industry. #Dipharma will contribute to this debate with a presentation by our colleague Simone Mantegazza, Research Laboratory Manager, on “The Difficult Road to Take Flow Chemistry from the Lab to the Plant”. The synergy between universities and industry is essential for #innovation and industrial #development. Universities and companies can exchange knowledge, collaborate on joint projects, and enhance graduate employability. Within the collaboration between the University of Milan and Dipharma, the potential of #flowchemistry is being explored, with a focus on commercially viable projects that are sustainable and scalable. The path to transitioning a flow chemistry project to full-scale production is not straightforward, but finding solutions is crucial to overcoming the challenges. Participation in the convention is free. For organizational reasons, please register on the site https://lnkd.in/dY_GSrNS by June 21. The program is available at the same link. To learn more about our innovative solutions, expertise, and capabilities, please contact us: https://lnkd.in/ermD5P2 Dipharma Francis S.r.l, Dipharma Inc., #DipharmaGroup; #CDMO, #APIs, #activepharmaceuticalingredient; #sustainability
-
-
The XLVIII edition of the “Attilio Corbella” International Summer School on Organic #Synthesis – ISOS 2024 – is coming. It will take place in Gargnano (BS, Italy) from the 16th to the 20th of June 2024, and #Dipharma is once again proud to be one of the sponsors. The ‘Attilio Corbella’ Summer School serves as a crucial hub for cultural enrichment and #scientific knowledge among organic chemists, providing outstanding opportunities to foster both scientific and interpersonal connections. Furthermore, we are pleased to inform that our colleague Veronica Pagliari, R&D Researcher, will present the poster “SYNTHESIS OF INTERMEDIATES USEFUL FOR THE PREPARATION OF ETRIPAMIL”. The aim of this poster is to suggest and develop new synthetic approaches for the convergent synthesis of Etripamil, a short-acting non-dihydropyridine L-type calcium-channel blocker, that has been formulated as a nasal spray useful for the patients who experience paroxysmal supraventricular tachycardia (PSVT). To read the digital poster, please click here: https://lnkd.in/dNz2iJEf To learn more about our innovative solutions, expertise, and capabilities, please contact us: https://lnkd.in/ermD5P2 More information about ISOS 2024 is available at: https://lnkd.in/e8_bim5v Dipharma Francis S.r.l, Dipharma Inc., #DipharmaGroup; #Chemistry, #Talent, #SummerSchool, #Synthesis, #ProcessChemistry #CDMO, #APIs, #activepharmaceuticalingredients, #Intermediates
-
-
We are excited to announce that Dipharma Group is a silver sponsor of the 2024 Biotech Outsourcing Strategies Basel event! Join us in Switzerland on June 19-20, where industry leaders in R&D outsourcing will converge to share insights and forge new partnerships. Looking for a reliable #CDMO to handle your #smallmolecule drug substance projects efficiently and within budget? Reach out to Andrea Frigerio, Exclusive Synthesis Program Manager and Business Development, to schedule a meeting. Andrea Frigerio is eager to discuss how Dipharma can support your development program, from early clinical phase to successful commercial launch. To join the event and connect with us: https://lnkd.in/dri3nixd To learn more about our technologies and services: www.dipharma.com Dipharma Francis S.r.l; Dipharma Inc.; #CDMO; #customsynthesis; #smallmolecule, #BOSBASEL2024; Bio2Business Ltd
-